Article

Smoothened Inhibitor, PF-04449913 Inhibits the Development of Myelofibrosis in a JAK2V617F Transgenic Mouse Model by Reducing TGF-β and MAPK Signaling Pathways

2025-05-09

Abstract excerpt

<title>Abstract</title> Treatment of JAK2V617F driven myeloproliferative neoplasms (MPNs) with Ruxolitinib (JAK inhibitor, JAKi) has shown limited disease-modifying benefits and has led to the search for other pathways as potential therapeutic targets for this disease. We investigated the effects of Smoothened inhibition (SMOi) using the small-molecule inhibitor PF-04449913 (PF-13) in a JAK2V617F transgenic mo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: db9fd7cd-8c9e-5b34-b662-79468cd71cc3
DOI: 10.21203/rs.3.rs-6580439/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Smoothened Inhibitor, PF-04449913 Inhibits the Development of Myelofibrosis in a JAK2V617F Transgenic Mouse Model by Reducing TGF-β and MAPK Signaling PathwaysDOI 10.21203/rs.3.rs-6580439/v1Read

Targeting hedgehog signaling in myelofibrosis and other hematologic malignanciesSemantic proximity Read

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signalingSemantic proximity Read

Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In MyelofibrosisSemantic proximity Read

Transcriptional regulation of SPROUTY2 by MYB influences myeloid cell proliferation and stem cell properties by enhancing responsiveness to IL-3.Semantic proximity Read

Loss of Ezh2 synergizes with JAK2 -V617F in initiating myeloproliferative neoplasms and promoting myelofibrosisSemantic proximity Read

The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14Semantic proximity Read

Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms.Semantic proximity Read

Sotatercept Reverses SIN3a Deficiency-Driven PAH by Reprogramming BMPR2/TGF-β-HIF-1α Signaling PathwaysSemantic proximity Read

SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm.Semantic proximity Read

Hedgehog pathway inhibitors: a patent review (2009 – present)Semantic proximity Read

Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.Semantic proximity Read

Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPNSemantic proximity Read